Sean Cunliffe has been appointed CEO of Sitka Biopharma Inc, a spinoff of CDRD Ventures Inc (see brief on this page). Cunliffe is a pharmaceutical sales and marketing executive with more than 30 years of experience working in big pharma. At Sitka he will work with founding scientists Dr Helen Burt and Dr Don Brooks (Univ of British Columbia) and Dr Martin Gleave (Vancouver Prostate Centre) to advance the firm's polymer technology platform for the treatment of bladder cancer to commercial viability. Prior to joining Sitka, Cunliffe held senior roles with Angiotech Pharmaceutical and Neuromed Pharmaceuticals (now Zalicus Inc, Cambridge MA). He also held several positions at Wyeth Pharmaceuticals and, Glaxo Wellcome. Cunliffe holds a BSc in biology from Queen's Univ and an MBA in finance from McMaster Univ….